Health Care/Hospital
MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
The company is revolutionizing regenerative healthcare through innovation,
clinical alignment, and GMP-grade excellence acrossSoutheast Asia
SAN ANTONIO, Dec. 15, 2025 /PRNewswire/ -- Frost & Sullivan
2025-12-15 17:00
1596
Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once-daily or potentially once-weekly oral dosing. - ASC50 had strong target engagement after a single oral dose, in...
2025-12-15 17:00
3943
Global Spotlight｜POGMENT Biomimetic Collagen "Stable Triple Helix" Breakthrough Stuns the World--Extraordinary and Breathtaking
CHENGDU, China, Dec. 15, 2025 /PRNewswire/ -- Recently, LivingPhoenix Regenerative Technologies has captured widespread attention with its world-first "Stable Triple-Helix Biomimetic Collagen" technology, making consecutive appearances at 12 high-level academic conferences in November. These eve...
2025-12-15 16:32
1475
Medit Announces 2025 Year-End Promotion
SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Medit, a global leader in 3D dental scanning solutions, announced the launch of "Medit's 2025 End of Year Promotion," a limited-time campaign delivering significant benefits to dental professionals worldwide. Dental professionals can learn more ab...
2025-12-15 16:00
1989
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
* Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient * The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressu...
2025-12-15 15:02
1362
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up ...
2025-12-15 14:06
2310
Manulife and Bupa Sign MoU for Strategic Collaboration in Hong Kong to Create a More Robust, Integrated Healthcare Network Offering Customers Greater Access and Choice
HONG KONG, Dec. 15, 2025 /PRNewswire/ -- Manulife (International) Limited ("Manulife") and Bupa International Limited ("Bupa") are pleased to announce today the signing of a Memorandum of Understanding ("MoU"), intended to establish a strategic collaboration inHong Kong that will provide customer...
2025-12-15 13:45
2558
Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder
SHANGHAI, Dec. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the launch of its 2030 Strategy, out...
2025-12-15 12:40
1870
AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List
SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- AbbVie ASEAN has been ranked #15 in
the inauguralFortune Best Companies to Work For Southeast Asia 2025 list, in
partnership with Great Place To Work®, highlighting workplaces acrossSingapore,
Malaysia, Thailand and the Philippines.
2025-12-15 09:00
3553
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Announcement Highlights: * Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. * The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CY...
2025-12-15 08:25
1651
ALL CONEC Signs MOU with MINIMAX to Accelerate Global Digital Dental Expansion
SEOUL, South Korea, Dec. 13, 2025 /PRNewswire/ -- ALL CONEC has signed a memorandum of understanding (MOU) with Australian digital dental company MINIMAX to jointly promote digital implant production, marking a strategic move to expand into global markets. The collaboration will validate implant...
2025-12-13 08:00
2888
Keeping Loved Ones Active and Healthy During the Holidays with VARON Oxygen Concentrators
NEW YORK, Dec. 12, 2025 /PRNewswire/ -- The holiday season
2025-12-12 23:16
2523
/DISREGARD RELEASE: Ractigen Therapeutics/
We are advised by Ractigen Therapeutics that journalists and other readers should disregard the news release, Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18 for Duchenne Muscular Dystrophy, issued7:30AM 12-Dec-2025 over PR Newswire, as the release contained erroneous information...
2025-12-12 23:10
2771
Strategic Partnership | Sanyou Bio and KanryBio Forge Partnership to Co-Develop Key Reagents and Products for Biomarker Assay Kits
SHANGHAI, Dec. 12, 2025 /PRNewswire/ -- On December 10, 2025, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and Wenzhou KanryBio Biotech Co., Ltd. ("KanryBio")announced a strategic collaboration agreement. The partnership will focus on the joint development of key reagents and p...
2025-12-12 22:00
3263
United Imaging Intelligence at RSNA 2025: Reshaping Medicine with AI Agents
SHANGHAI, Dec. 12, 2025 /PRNewswire/ -- Under the theme "Imaging the Individual", RSNA 2025 challenged the radiology community to push into new frontiers and close the gap between personalized care and global health disparities. This year,United Imaging Intelligence (UII), the AI-focused subsidi...
2025-12-12 22:00
3227
Global Attention: POGMENT Biomimetic Collagen "Stable Triple-Helix Breakthrough" --Unconventional and Astonishing
— LivingPhoenix Forum's 12 Conference Presentation Ignite International and Domestic Academia, Hailed by Academicians as the "iPhone Moment for Extracellular Matrix Research" CHENGDU, China, Dec. 12, 2025 /PRNewswire/ -- LivingPhoenix Regenerative Technologies has drawn widespread international ...
2025-12-12 21:46
4348
Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy
NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH...
2025-12-12 21:35
2772
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
* Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023. * The partnership combines Insilico's generative AI ...
2025-12-12 20:00
2303
Smartee Strengthens Clinical Engagement in the DACH Region with First GS Summit in Cologne and Presence at TPAO Congress
COLOGNE, Germany, Dec. 12, 2025 /PRNewswire/ -- Smartee Denti-Technology hosted its first GS-focused clinical summit inCologne on November 27, deepening its collaboration with orthodontists across the DACH region. Although Smartee has operated inGermany for more than 2 years through its local sub...
2025-12-12 17:26
1466
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study wi...
2025-12-12 10:31
2939
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 272 media titles]
2025-12-30 20:12
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 262 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 259 media titles]
2025-12-29 14:27